Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

1.870 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Mar 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,495
Open 1.870
Bid (Size) 1.870 (900)
Ask (Size) 1.900 (1,000)
Prev. Close 1.870
Today's Range 1.870 - 1.870
52wk Range 1.580 - 3.840
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-28.6%
-28.6%
1 Month
-13.0%
-13.0%
3 Month
-22.4%
-22.4%
6 Month
-28.1%
-28.1%
1 Year
-11.8%
-11.8%

More News

Read More
News headline image
NRx Builds Momentum From FDA Progress To Strategic Expansion
Via NewMediaWire
News headline image
NRx Builds Momentum From FDA Progress To Strategic Expansion
Via TheNewswire.com
Why Did NRXP Stock Surge 21% Pre-Market Today? ↗
Via Stocktwits
News headline image
FDA Meeting Indicates Path to New Drug Application with Real World Data and Broader Indication of NRX-100 (Ketamine) for Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Milestone Patient Data Eclipsing 70,000 on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Licenses Real-World Evidence From 70,000 Patients to Support FDA Accelerated Approval of NRX-100
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Partners With neurocare Group AG To Build Nationwide Neuroplastic Care Network
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
More Than 1 Million Suicidal Depression Cases Per Year May Be Treated by 2030 via New Indication for Augmentation of Transcranial Magnetic Stimulation: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment
Via Investor Brand Network
News headline image
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA Submission for Abbreviated New Drug Application; $750 Million Market for Suicidal Depression Market Awaits Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date
Via Investor Brand Network
NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Schedules Corporate Update Call for Dec. 2
Via Investor Brand Network
News headline image
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at NobleCon21
Via Investor Brand Network

Frequently Asked Questions

Is NRX Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, NRX Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does NRX Pharmaceuticals, Inc. - Common Stock trade on?
NRX Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock is NRXP on the Nasdaq Stock Market
What is the current price of NRX Pharmaceuticals, Inc. - Common Stock?
The current price of NRX Pharmaceuticals, Inc. - Common Stock is 1.870
When was NRX Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of NRX Pharmaceuticals, Inc. - Common Stock was at 03/04/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.